AstraZeneca 'disappointed but confident' over Nexium patent decision in Europe
This article was originally published in Scrip
AstraZeneca has informed Scrip that it "has confidence in its intellectual property portfolio protecting Nexium (esomeprazole)" following the decision of the European Patent Office to revoke one of its patents covering the proton pump inhibitor for oral administration (patent EP 1 020 461) following thirteen oppositions from generic drug manufacturers including Teva. However, it was "disappointed" by the ruling.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.